Biotechnology

Undercover footage shows disturbing treatment of beagles at a Toronto lab, sparking calls for investigation and questioning Canada's animal research laws.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.

As it turns 60, Melmark adds two powerhouse leaders with deep personal ties to its mission, signaling a new era of strategic growth and innovation.

A new partnership combines scalable stem cell technology with AI-driven organoids to create personalized models, offering new hope for rare disease patients.

Northwell Health launches a new research center to study psilocybin and MDMA, aiming to find breakthrough treatments for anxiety and schizophrenia.

A new collaboration with Multiply Labs aims to use advanced robotics to automate cell therapy production, potentially making these cures accessible to all.

Amid federal funding threats, state leaders and industry forge a strategic alliance to protect Connecticut’s $7B life sciences sector and fuel innovation.

An oral drug for Huntington's disease shows early success, improving patient scores where a decline was expected, fueling hope for a breakthrough treatment.

A pivotal FDA meeting moves a novel drug forward for Dementia with Lewy Bodies, a disease with no approved therapies, offering new hope to patients.

A new drug targeting a genetic form of Parkinson's shows promise as its late-stage trial nears completion, offering hope for a precision treatment.

BioTalent Canada's latest awards highlight how inclusivity, diversity, and equity are becoming key drivers of innovation and profit in the bioscience sector.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

China approves Libevitug, a first-in-class drug for the most severe form of hepatitis, marking a major milestone for patients and global biotech innovation.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

Frequency tech firm Hapbee adds a marketing maestro to its board, aiming to rebrand from niche gadget to a mainstream player in the booming wellness economy.

A strategic investment from Krieger Capital will fuel Global Key Solutions' AI platform, which transforms complex regulatory data into actionable safety insights.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.